Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of WD-1603 at Different Dosing Intervals in Healthy Participants
NCT07442591Phase 1Completed
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of WD-1603 in Parkinson's disease (PD) (3 arms), sponsored by Shanghai WD Pharmaceutical Co., Ltd. Primary endpoints: Maximal Plasma Concentration at 24 hours, Area under the Concentration versus Time Curve from 0 to Time t at 24 hours and 9 more. Started Mar 2026; status: completed.
02
Drugs
WD-1603
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07442591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07442591.